Orexigen Seeks FDA OK for Obesity Drug

Xconomy San Diego — 

Orexigen Therapeutics (NASDAQ: OREX), the San Diego-based developer of weight loss drugs, said today it has turned in its application for FDA approval of its first marketed product in the U.S. The drug, a combination of bupropion and naltrexone (Contrave), has been studied in more than 4,500 patients, the company said. If approved, Orexigen could be in position to compete with new drugs from San Diego-based Arena Pharmaceuticals and Mountain View, CA-based Vivus, which are also being considered by FDA reviewers.